Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
decitabine + vemurafenib + cobimetinib
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This investigational combination therapy consists of three active ingredients: decitabine, vemurafenib, and cobimetinib. It is being evaluated in a Phase 1/2 clinical trial (NCT01876641) led by Dr. Mohammed M. Milhem at the University of Iowa for the treatment of BRAF-mutated metastatic melanoma. The regimen combines standard-of-care MAPK pathway inhibition—using the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib—with low-dose decitabine, a DNA methyltransferase inhibitor. The rationale for this triple combination is that epigenetic modulation via decitabine may reverse or prevent resistance to BRAF/MEK inhibitors, potentially improving response rates and durability in patients with resistant or advanced disease.
- Other names
- Decitabine with Vemurafenib and CobimetinibVemurafenib + Cobimetinib + DecitabineVemurafenib + Cobimetinib-Mohammed M Milhem-melanoma (metastatic)
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)DNMT1 (DNA (cytosine-5)-methyltransferase 1)BRAF V600EMEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on decitabine + vemurafenib + cobimetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on decitabine + vemurafenib + cobimetinib.